Payers rebel against Gilead over cost of hepatitis C pill

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Insurers, patients and other payers are pushing back against what they believes is the exorbitant fee that Gilead (GILD) is charging for its new hepatitis C drug Sovaldi.

Previously: Pfizer lung-cancer drug fails in two Phase III studies

The pill costs $1,000 a pop, or $84,000 for a 12-week treatment vs $66,000 for the current standard of care.

The likes of Express Scripts (ESRX), Catamaran (CTRX), Aetna (AET) and CVS Caremark (CVS) are among those who are looking to pit similar treatments against each other, declining to provide coverage for some, and refusing to pay a premium based on one therapy being more convenient than another.

This was corrected on 01/27/2014 at 07:51 AM. The headlines incorrectly stated the action of the payers against Gilead's drug.